Figure 3 from Evaluation of Ferroptosis as a Biomarker to Predict Treatment Outcomes of Cancer Immunotherapy

Ferroptosis-high tumors showed attenuated immunosenescence and enhanced immune response. A and B, Gene set enrichment analysis to examine ferroptosis enrichment and activation of the immune response in ferroptosis-high and ferroptosis-low tumors in the IMvigor210 cohort. C and D, Comparison of the IFN-γ signature score and expanded immune score of ferroptosis-low and ferroptosis-high tumors in the IMvigor210 cohort. E, Heatmap shows the correlation between ferroptosis and the expression of IFN-γ immune response signature genes in tumors of the IMvigor210 cohort. F, Heatmap shows the correlation between ferroptosis and the expression of immunosenescence suppressor genes in tumors of the IMvigor210 cohort. *, P < 0.05; ***, P < 0.001. NES, normalized enrichment scale.